Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06600607
Registration number
NCT06600607
Ethics application status
Date submitted
13/09/2024
Date registered
19/09/2024
Date last updated
4/05/2025
Titles & IDs
Public title
Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacodynamic Effects of Pregabalin in Healthy Male Adults
Query!
Secondary ID [1]
0
0
LTG-OBS-102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pain Detection
0
0
Query!
Pain Threshold
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - pregabalin 300 mg
Other interventions - Placebo
Other: Schedule A - participants receive pregabalin 300mg in treatment period 1, and receive placebo in treatment period 2
Other: Schedule B - participants receive placebo in treatment period 1, and receive pregabalin 300mg in treatment period 2
Treatment: Drugs: pregabalin 300 mg
pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain
Other interventions: Placebo
biologically inactive placebo comparator
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change from baseline pain score after dosing with pregabalin vs. placebo
Query!
Assessment method [1]
0
0
Numerical Pain Rating Scale (NPRS) will be assessed during Cold Pressor Tests at various time points for time to reach Pain Detection Threshold (PDT) and time to reach Pain Tolerance Threshold (PTT)
Query!
Timepoint [1]
0
0
0-12 hours during each treatment period
Query!
Primary outcome [2]
0
0
Time to reach Pain Detection Threshold (PDT) and Pain Tolerance Threshold (PTT) after dosing with pregabalin vs placebo
Query!
Assessment method [2]
0
0
Stopwatches will be used during each cold pressor test to determine time for subject to reach PDT and PTT
Query!
Timepoint [2]
0
0
0-12 hours during each treatment period
Query!
Eligibility
Key inclusion criteria
1. Male participants aged 18 to 55 years, inclusive, at the time of signing the informed consent.
2. Overtly healthy with no clinically relevant abnormalities based on the medical history, physical examinations, clinical laboratory evaluations, and 12-lead ECG that, in the opinion of the investigator, would affect participant safety.
3. Body mass index (BMI) within the range of 18-32 kg/m2 (inclusive).
4. Male participants are eligible to participate if they agree to refrain from donating semen. Plus, agree to use a male condom when having sexual intercourse with woman of childbearing potential or women who are currently pregnant.
5. Capable of giving signed informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption.
2. Clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator, unacceptably increase the participant's risk by participating in the study.
3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), >1.5 x upper limit of normal (ULN) at Screening.
4. Total bilirubin > 1.5 x ULN (for participants with known Gilbert's syndrome these criteria only apply if total bilirubin > 1.5 x ULN as long as direct bilirubin is = 1.5 x ULN) at Screening.
5. Estimated glomerular filtration rate (eGFR) <80 mL/min based on serum creatinine levels using the 2021 chronic kidney disease epidemiology (CKD-EPI) creatinine equation at Screening.
6. Creatinine phosphokinase is = 2 × ULN at Screening.
7. Any of the protocol defined abnormalities on 12-lead ECG or blood pressure (BP) at Screening, confirmed by repeat.
8. Use of prescription drugs = 14 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1, use of over-the-counter drugs, herbal medications, or vitamin supplements = 7 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1 or use of antibiotics and systemic steroids = 28 days prior Day 1. The Sponsor may allow exceptions only if the medication's administration is deemed unlikely to confound safety.
9. Any vaccination = 14 days prior to Day 1 or anticipated vaccination while participating in the study.
10. Receipt of an investigational product or device, or participation in a drug research study = 28 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1.
11. Receipt of an investigational biologic / monoclonal antibody within 180 days (or 5 half-lives, whichever is longer) prior to Day 1.
12. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at Screening.
13. Presence of positive hepatitis C antibody test result at Screening.
14. Positive for Coronavirus Disease 2019 (COVID-19) suggesting active infection at Screening or on Day 1.
15. Positive human immunodeficiency virus (HIV) at Screening.
16. Presence of any condition for which pregabalin administration is contraindicated.
17. Smoking, vaping or use of tobacco or any products containing nicotine = 14 days prior to Day 1.
18. Consumption of alcohol within 48 hours prior to Day 1 and/or food and beverages containing methylxanthines (caffeinated coffee, caffeinated tea, caffeinated soda, and chocolate) within 48 hours of Day 1, and grapefruit, grapefruit juice, Seville oranges, or Seville orange juice = 14 days prior to Day 1.
19. Positive urine drug screen, urine cotinine test, or alcohol breath test at Screening or on Day 1.
20. Donation of over 500 mL blood = 3 months prior to Day 1.
21. Has known psychiatric disorders that would interfere with the cooperation with the requirements of the study.
22. Participant is under legal custodianship.
23. Pain conditions that may require analgesic treatment during the study period/history of opioid medication use.
24. Hand/arm/skin conditions impacting ability to participate in cold pressor assessment.
25. Recent serious injury, surgical procedure, or medical condition which, in the opinion of the investigator, unacceptably increases the participant's risk by being included in the study.
26. Meets protocol defined Pain Tolerance Threshold (PTT) in any of the 5 predose cold pressor tests.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 0
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/10/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/10/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
20
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Christchurch
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Latigo Biotherapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test. The study will be conducted at a single center in New Zealand.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06600607
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Chief Medical Officer
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
626-862-7778
Query!
Fax
0
0
Query!
Email
0
0
nsingla@latigobio.com
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06600607
Download to PDF